title: Observations from the OMERACT Drug Safety Summit, May 2008.
abstract: Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions.
authors.affiliation: Harvard Medical School, Boston, MA, USA. omeract@uottawa.ca
authors.forename: Lee S
authors.initials: LS
authors.lastname: Simon
authors.forename: C Vibeke
authors.initials: CV
authors.lastname: Strand
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
authors.forename: Peter M
authors.initials: PM
authors.lastname: Brooks
authors.forename: David
authors.initials: D
authors.lastname: Henry
authors.forename: Peter S
authors.initials: PS
authors.lastname: Tugwell
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055808:Drug Discovery; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*; D018570:Risk Assessment
chemical_list: D018501:Antirheumatic Agents